DR. TIMOTHY J CARDOZO, MD-PHD
Dermatology at 37 St, New York, NY

2005008, Apr 21, 2005

Oct 17, 2003

10/689530

Timothy Cardozo - New York NY, US
John Pui - Ann Arbor MI, US

A61K031/7072, A61K031/513

514049000, 514269000

The present invention relates to the treatment of inflammatory skin conditions, including psoriasis, with a prodrug of 5-fluorouracil. The invention relates to methods for treatment of psoriasis with capecitabine, an oral prodrug of 5-fluorouracil.

2013028, Oct 31, 2013

Sep 28, 2011

13/876918

Timothy Cardozo - New York NY, US
Susan Zolla-Pazner - New York NY, US
Abraham Pinter - New York NY, US
Chavdar Krachmarov - Livingston NJ, US
Shan Lu - Franklin MA, US
Shixia Wang - Northborough MA, US
Maxim Totrov - San Diego CA, US

NEW YORK UNIVERSITY - New York NY
UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY - Newark NJ
UNIVERSITY OF MASSACHUSETTS - Boston MA
MOLSOFT LLC - San Diego CA

C07K 14/00

4241851, 530350, 530327, 435 72, 435 5

The present invention is directed to a recombinant immunogenic polypeptide. The polypeptide includes a loop peptide inserted into an immunogenic scaffold protein. The loop polypeptide has an amino acid sequence which presents the 3074 mAb- or the 2219/2557 mAb-targeted epitope of the HIV gp120 protein and not other known epitopes of the HIV gp120 protein. When used as an immunogen, the polypeptide induces an antibody response which neutralizes heterologous HIV-1 viruses in a pattern similar to that observed for the 3074 mAb- or the 2219/2557 mAb-targeted epitope, respectively. Pharmaceutical compositions containing the immunogenic polypeptide as well as methods of making and using it are also disclosed.

7638319, Dec 29, 2009

Mar 7, 2006

11/369010

Timothy Cardozo - New York NY, US
Susan Zolla-Pazner - New York NY, US

New York University - New York NY

C12N 7/00, C12Q 1/00

4352351, 435 4

Newly discovered structural characteristic of the gp120 V3 loop have resulted in a “rule” or algorithm, that is used in a method for determining whether a subject is infected with HIV-1 virus that expresses selectivity for CXCR4 or CCR5 chemokine receptors. A positively charged surface patch defined by V3 loop residues 11 and 24 or 25 at the base of the β-strands in the V3 loop and the homologous β2-β3 chemokine hairpin is responsible for CXCR4 receptor selection. Thus a method for detecting the presence of HIV-1 virus that is selective for X4-co-receptors in a subject infected with HIV-1 or suspected of being infected, from the amino acid sequence of at least a part of the HIV-1 gp120 V3 region peptide that includes residues 11, 24 and 25, or from the nucleotide sequence of a nucleic acid encoding said V3 region peptide, is disclosed.

2009009, Apr 16, 2009

Aug 20, 2008

12/195318

Susan ZOLLA-PAZNER - New York NY, US
Miroslaw K. Gorny - Harrison NY, US
Timothy J. Cardozo - New York NY, US
Ruben Abagyan - La Jolla CA, US
Maxim Totrov - San Diego CA, US
Shan Lu - Franklin MA, US
Abraham Pinter - Brooklyn NY, US

New York University - New York NY
Molsoft LLC - La Jolla CA
University of Massachusetts - Boston MA
University of Medicine and Dentistry of New Jersey - Newark NJ

A61K 39/42, C07K 16/10, A61P 31/18

4241601, 5303894

Insertion of HIV-1 V3 loop peptides from the viral glycoprotein gp120 into selected, immunogenic scaffold proteins results in a recombinant polypeptide that is a potent V3 immunogen. V3 immunogens include natural and consensus V3 sequences and cyclic and reverse peptides. Preferred scaffold proteins are Cholera Toxin subunit B and homologues thereof including closely related enterotoxins. Such immunogenic polypeptides induce broadly reactive anti-gp120 antibodies specific for V3 epitopes that can neutralize heterologous HIV-1 subtypes and strains. These polypeptide, methods for preparing them, and methods for inducing anti-gp120 (V3-specific) antibody) responses using them are disclosed.

2013007, Mar 21, 2013

Sep 12, 2012

13/612300

Timothy CARDOZO - New York NY, US
Xiangpeng KONG - New York NY, US
Susan ZOLLA-PAZNER - New York NY, US

NEW YORK UNIVERSITY - New York NY

C07K 7/08, C07K 7/64, A61K 38/19, C07K 16/10, G01N 33/68, C07K 14/245, C07K 14/28, A61K 39/21

4241921, 530300, 530327, 530326, 530350, 530317, 4242081, 5303894, 435 792

The present invention relates to an isolated immunogenic peptide comprising a V2 loop fragment from HIV surface envelope glycoprotein gp120. This peptide binds specifically with antibodies in blood of patients vaccinated with a vaccine that has shown protection from HIV-1 infection, does not react with blood of matched patients who did not receive the vaccine, and can, therefore, elicit anti-HIV-1 antibodies which protect against HIV-1 infection. Other aspects of the present invention relate to an isolated immunogenic polypeptide comprising the peptide inserted into an immunogenic scaffold protein, a vaccine composition comprised of the immunogenic peptide and an immunologically or pharmaceutically acceptable vehicle or excipient as well as methods of inducing an immune response against HIV-1 and methods of detecting HIV-1.

2011028, Nov 24, 2011

May 19, 2011

13/111769

Timothy CARDOZO - New York NY, US
Hong WANG - New York NY, US
David Ron - Cambridge, GB

NEW YORK UNIVERSITY - New York NY

A61K 31/536, C12Q 1/48, A61K 31/519, A61K 31/496, A61K 31/4166, A61K 31/4245, A61K 31/433, A61K 31/24, A61K 31/428, A61K 31/225, C07D 487/04, C07D 417/14, C07D 403/06, C07D 413/12, C07D 285/135, C07C 69/76, C07D 277/62, C07C 69/34, A61P 35/00, A61P 25/28, A61P 9/10, A61P 25/00, A61P 3/04, A61P 37/00, A61P 25/16, A61P 19/02, A61P 37/06, A61P 1/00, G06G 7/60, C40B 30/02

5142305, 506 8, 435 15, 5142593, 51425402, 514389, 514364, 514363, 514534, 514367, 514548, 544281, 544369, 5483121, 548125, 548139, 560 61, 548180, 560194, 544 73, 703 11

The present invention relates to a method of identifying compounds useful in inhibiting protein kinase-like endoplasmic reticulum protein kinase (PERK). The method comprises providing a first model comprising PERK active domains, where the said active domains are selected from the group consisting of the peptide spanning from amino acid residue Asp144 to amino acid residue Ser191 of SEQ ID NO: 1 and a peptide comprising the amino acid residue at position 7 of SEQ ID NO: 1, providing one or more candidate compounds, evaluating contact between the candidate compounds and the first model to determine which of the one or more candidate compounds have an ability to bind to and/or fit in the first model, and identifying the compounds which, based on said evaluating, have the ability to bind to and/or fit in the first model as compounds potentially useful for inhibiting PERK. The present invention further relates to compounds that can be used for inhibition of PERK, for example human PERK, and methods related to treatment of PERK-mediated diseases.